Acrivon Therapeutics Inc
ACRV
NASDAQ
Biotechnology
$1.95
USD
+0.10 (+5.41%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $74.48M
Volume 752.9K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-74.22M
TTM
+13.6%
YoY
Operating Cash Flow
$-62.92M
TTM
+11.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 6.5 | 6.0 | 5.4 | 4.7 | 4.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 22.6 | 19.7 | 20.1 | 19.9 | 18.7 |
Operating Income | -22.6 | -19.7 | -20.1 | -19.9 | -18.7 |
EBITDA | -22.3 | -19.3 | -19.8 | -19.5 | -18.3 |
Other Income / Expense | -0.1 | -0.1 | -0.1 | -0.1 | -0.2 |
Total Other Income / Expense | 1.6 | 1.5 | 1.1 | 0.9 | 0.7 |
Income Before Income Taxes | -21.0 | -18.2 | -19.0 | -19.0 | -18.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -21.0 | -18.2 | -19.0 | -19.0 | -18.0 |
Consolidated Net Income / Loss | -21.0 | -18.2 | -19.0 | -19.0 | -18.0 |
Net Income Attributable to Common Shareholders | -21.0 | -18.2 | -19.0 | -19.0 | -18.0 |
Basic EPS | -$0.55 | -$0.47 | -$0.49 | -$0.49 | -$0.43 |
Diluted EPS | -$0.55 | -$0.47 | -$0.49 | -$0.49 | -$0.43 |
Basic Shares Outstanding | 38.5M | 38.6M | 38.7M | 38.7M | 41.8M |
Diluted Shares Outstanding | 38.5M | 38.6M | 38.7M | 38.7M | 41.8M |